Kuros BiosciencesCSBTF 71 Days Inventory is 267.41 as of Dec. 2025, which is 76% above its 10-year median of 152.13. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $54.72 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 786 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 79.52% on this metric.
The historical rank and industry rank for Kuros Biosciences's Days Inventory or its related term are showing as below:
CSBTF'
s Days Inventory Range Over the Past 10 Years
Min: 24.3 Med: 152.13 Max: 347.42
Current: 311.6
During the past 13 years, Kuros Biosciences's highest Days Inventory was 347.42. The lowest was 24.30. And the median was 152.13.
CSBTF's Days Inventory is ranked worse than 79.52% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 179.86
vs CSBTF: 311.60
Kuros Biosciences's Days Inventory
increased
from Dec. 2024 (133.60) to Dec. 2025 (267.41).
It might indicate that Kuros Biosciences's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Kuros Biosciences's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.68.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Kuros Biosciences's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.17.
Kuros Biosciences (OTCPK:CSBTF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Kuros Biosciences's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Kuros Biosciences's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Kuros Biosciences Days Inventory Related Terms
Kuros Biosciences Days Inventory Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Kuros Biosciences's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Days Inventory distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (CSBTF) has a Days Inventory of 267.41 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Kuros Biosciences and its competitors. This is 76% above median its historical median of 152.13. Over the past decade, Kuros Biosciences' Days Inventory has ranged from 24.30 to 347.42. According to the industry distribution chart, Kuros Biosciences ranks #625 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 79.5%.
Is Kuros Biosciences' Days Inventory too high?
Kuros Biosciences' current Days Inventory of 267.41 is 76% above median its 10-year median of 152.13. Over the past 10 years, this metric has ranged from a low of 24.30 to a high of 347.42. The Medical Devices & Instruments industry median Days Inventory is 179.86. Kuros Biosciences' value of 267.41 is 48.7% above this industry median. Based on the distribution chart, Kuros Biosciences ranks #625 out of 786 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Days Inventory compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #625 out of 786 companies for Days Inventory. This places Kuros Biosciences in the lower half of its industry. The industry median Days Inventory is 179.86. Kuros Biosciences' value of 267.41 is 48.7% above this benchmark. Historically, Kuros Biosciences' own Days Inventory has ranged from 24.30 to 347.42 over the past decade. While the company's 10-year median is 152.13 vs. the industry median of 179.86, Kuros Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 179.86, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current Days Inventory of 267.41 is 48.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 179.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current Days Inventory is 267.41, which is 76% above median its own 10-year median of 152.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.72, compared to a current price of $22.72 — trading 58.5% below its estimated fair value. The current Days Inventory is 267.41, which is 76% above median its 10-year median of 152.13 and 48.7% above the Medical Devices & Instruments industry median of 179.86. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Days Inventory is 267.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $22.72 is trading 58.5% below its estimated GF Value™ of $54.72.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
Days Inventory: 267.41 (76% above median its 10-year median of 152.13)
GF Value™: $54.72 vs. price of $22.72 (58.5% below fair value)
Industry Position: 48.7% above the Medical Devices & Instruments median (#625 of 786)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score
Get the complete analysis for CSBTF
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
